News | January 25, 2024
Shilpa Medicare directed to to pay damage to Celltrion
The matter of Arbitration between Shilpa Medicare Limited and Celltrion towards supply and distribution agreement
The matter of Arbitration between Shilpa Medicare Limited and Celltrion towards supply and distribution agreement
GC1130A has previously achieved notable milestones by securing both RPDD and ODD from the U.S. FDA in January 2023
Transaction delivers KarXT, a first-in-class M1/ M4 muscarinic receptor agonist with differentiated efficacy and safety
Expands patient reach to remotest towns by furthering investment in GoApptiv
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
Syngene gains access to ERS Genomics' foundational CRISPR/Cas9 patent portfolio, ushering in a new era of technical innovation in India for its global partners
Three-point improvement achieved in Sex Ratio at Birth from 904 in 2017-19 to 907 in 2018-20
Glenmark's Zita portfolio of medicines have been benefiting around 1.75 million Type 2 diabetic patients annually
Venus Remedies' oncology wing has also secured marketing authorisation from Myanmar for another chemotherapy drug
The launch of Elores in Ecuador is expected to open the doors for the entry of the novel antibiotic adjuvant entity in other important Latin American countries
Subscribe To Our Newsletter & Stay Updated
